Ian McLeod
Comptroller/Controller/Auditor bei ANIKA THERAPEUTICS, INC.
Profil
Ian McLeod is currently the Chief Accounting Officer & Vice President at Anika Therapeutics, Inc. He previously worked as a Controller at ABIOMED, Inc. from 2007 to 2017 and as a Corporate Controller at Idenix Pharmaceuticals LLC from 2004 to 2007.
Mr. McLeod has an undergraduate degree from the University of Western Ontario and an MBA from McMaster University.
Aktive Positionen von Ian McLeod
| Unternehmen | Position | Beginn |
|---|---|---|
| ANIKA THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 01.07.2021 |
Ehemalige bekannte Positionen von Ian McLeod
| Unternehmen | Position | Ende |
|---|---|---|
| IDENIX PHARMACEUTICALS INC | Comptroller/Controller/Auditor | 01.11.2007 |
| ABIOMED, INC. | Comptroller/Controller/Auditor | - |
Ausbildung von Ian McLeod
| University of Western Ontario | Undergraduate Degree |
| McMaster University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ANIKA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
ABIOMED, Inc.
 ABIOMED, Inc. Medical SpecialtiesHealth Technology ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It distributes its products under the Impella brand. The company was founded by David M. Lederman in 1981 and is headquartered in Danvers, MA. | Health Technology |
Idenix Pharmaceuticals LLC
 Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
